Group 1 - The announcement states that 10 pharmaceutical companies, including Harbin Pharmaceutical Group, have passed the compliance inspection for Good Manufacturing Practice (GMP) as per the requirements of the Drug Administration Law and the National Medical Products Administration [3][4] - The inspection was conducted on various production lines, including penicillin oral preparations and solid dosage forms, across different facilities in Heilongjiang Province [3][4] - The compliance inspection took place between August and September 2025, with specific dates and production lines detailed for each company [3][4] Group 2 - The companies inspected include Harbin Guokang Pharmaceutical Co., Harbin Sanlian Pharmaceutical Co., and Heilongjiang Boyu Pharmaceutical Co., among others, indicating a broad scope of compliance across the local pharmaceutical industry [3][4] - The inspection results are part of ongoing efforts to ensure quality standards in pharmaceutical manufacturing, which is critical for maintaining public health and safety [3][4] - The announcement serves as a public record of compliance, which may enhance the reputation and marketability of the companies involved [3][4]

Report Industry Investment Rating - The document does not provide the report industry investment rating [1][2] Core Views - With the improvement of the China-Europe Railway Express control system, the completion of the capacity expansion and upgrading of cross-border railway lines in Heilongjiang, and the stabilization of the overseas political situation, Heilongjiang's import and export trade will be further enhanced, supporting the long-term stable development of the provincial economy [3][9] - In the A-share market sentiment continues to warm up and the domestic economic improvement trend is more clear, listed companies in Heilongjiang Province are expected to maintain good performance [3][20] - As China's economic structure transformation deepens, the consumer market demand is expected to continue to improve [34] Summary by Directory 1. Heilongjiang Current News Tracking - As of October 24, 2025, the import volume of Tongjiang Railway Port reached 517 million tons, setting a new high for the same period. The port has taken measures to improve customs clearance and transportation efficiency, and the ongoing upgrade projects are expected to increase the cargo throughput by 40% and enrich the categories of imported and exported goods [3][9] - The 27th Harbin Ice and Snow World is upcoming, with the largest area in history, more ice and snow sculptures, diverse technological elements, and expanded entertainment and performance projects. The standard adult ticket price remains at 328 yuan, and the pre-sale tickets are on sale [10] - Since the 14th Five-Year Plan, Heilongjiang Province has made breakthroughs in scientific and technological research, with 16 billion yuan invested in key R & D programs. In the future, it will strengthen organized scientific research to support the construction of a modern industrial system [11][12] 2. Financial Market Data Tracking - Since October, the Korea Composite Index and the Nikkei 225 have led in returns, while the ChiNext Index and the Hang Seng Index in China have declined. Among industries, coal, banking, and power equipment have performed well, while media, automotive, and computer sectors have adjusted [13][14] - From October 20 to 24, the Shanghai Composite Index stood above 3900 points again, with most sectors rising. The communication and electronics sectors were the most prominent [17] - Since October, the Heilongjiang sector index has risen by 3.81%, with 29 listed companies achieving positive returns and 10 declining in the statistical period. Some companies like Baotailong had significant increases [3][18][20] 3. Domestic Macroeconomic Data Operation - In September, China's industrial added value above designated size increased by 6.5% year-on-year and 0.64% month-on-month. Different industries and economic types showed varying degrees of growth, indicating an overall improvement in business conditions [22][23] - In the first three quarters of 2025, the national fixed - asset investment (excluding rural households) decreased by 0.5% year-on-year, with different trends in different industries [29] - In September, the total retail sales of consumer goods were 4.1971 trillion yuan, a year-on-year increase of 3.0%. From January to September, the cumulative total was 36.5877 trillion yuan, with a year-on-year increase of 4.5%, showing the activation of market vitality and the release of consumption potential [32]

关于参与竞拍资产暨关联交易的进展公告 证券代码：002900 证券简称：哈三联 公告编号：2025-070 哈尔滨三联药业股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、交易基本情况 哈尔滨三联药业股份有限公司（以下简称"公司"）于 2025 年 10 月 23 日召 开第四届董事会第二十六次会议，审议通过《关于拟参与竞拍资产暨关联交易的 议案》，同意公司参与黑龙江威凯洱生物技术有限公司（以下简称"威凯洱生物"） 破产资产竞拍。本次交易构成关联交易，不构成《上市公司重大资产重组管理办 法》规定的重大资产重组，不构成重组上市，无需经过有关部门批准。根据《深 圳证券交易所股票上市规则》《公司章程》等有关规定，本次关联交易事项在公 司董事会审批权限内，无需提请股东大会审议。 具体内容详见公司于 2025 年 10 月 25 日在指定信息披露媒体《中国证券报》、 《上海证券报》、《证券时报》及巨潮资讯网（http://www.cninfo.com.cn）上披 露的《关于拟参与竞拍资产暨关联交易的公告》（公告编号：2025-067）。 2025 年 1 ...

证券代码：002900 证券简称：哈三联 公告编号：2025-069 哈尔滨三联药业股份有限公司 关于公司参与全国药品集中采购拟中标的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 本次集中采购是国家组织的第十一批药品集中带量采购，采购周期中，医疗 机构将优先使用本次药品集中采购中标药品，并确保完成约定采购量。若公司后 续签订采购合同并实施，将进一步扩大相关产品的销售，提高市场占有率，提升 公司品牌影响力，对公司具有积极的影响。 三、风险提示 | 序 | 拟中标 | 拟中标品 | 适应症 | 规格 | 包装数量 | 拟中选价格 | | --- | --- | --- | --- | --- | --- | --- | | 号 | 企业 | 种 | | | | | | 1 2 | 公司 | 罗沙司他 胶囊 | 本 品 适 用 于 慢 性 肾 脏 病 (CKD)引起的贫血，包括透 析及非透析患者。 | 20mg 50mg | 粒/板×3 1 板/盒 | 1.68 元/盒 元/盒 3.39 | | 3 | | 注射用氯 诺昔康 | 手术后急性中度疼痛的短期 治 ...

Core Viewpoint - The company reported a significant decline in both revenue and net profit for the third quarter of 2025, primarily due to the impact of national drug procurement policies and increased market competition for certain products [1] Financial Performance - The company's third-quarter revenue was 168 million yuan, representing a year-on-year decrease of 46.83% [1] - The net profit for the third quarter was -116 million yuan [1] - For the first three quarters of 2025, the total revenue was 581 million yuan, down 30.75% year-on-year [1] - The net profit for the first three quarters was -209 million yuan, with a basic earnings per share of -0.66 yuan [1] Market Conditions - The decline in sales prices for certain products is attributed to the effects of national drug procurement policies and intensified competition in the market for non-collection-based formulations [1]

Core Viewpoint - The company reported significant declines in both revenue and net profit for the third quarter and the first three quarters of 2025, primarily due to the impact of national drug procurement policies and increased market competition for certain products [1] Financial Performance - The company's third-quarter revenue was 168 million yuan, a year-on-year decrease of 46.83% [1] - The net profit for the third quarter was -116 million yuan [1] - For the first three quarters of 2025, the total revenue was 581 million yuan, reflecting a year-on-year decline of 30.75% [1] - The net profit for the first three quarters was -209 million yuan, with a basic earnings per share of -0.66 yuan [1] Market Conditions - The decline in sales prices for some products was attributed to the effects of national drug procurement policies and intensified competition in the market for certain non-collection formulation products [1]

Group 1 - Company Hasi Lian reported a revenue of approximately 581 million yuan for the first three quarters of 2025, representing a year-on-year decrease of 30.75% [1] - The net profit attributable to shareholders of the listed company was a loss of approximately 209 million yuan, with a basic earnings per share loss of 0.66 yuan [1] - The current market capitalization of Hasi Lian is 4.5 billion yuan [2] Group 2 - The Chinese innovative drug sector has sold overseas authorizations worth 80 billion US dollars this year [2] - The secondary market for biomedicine is experiencing a boom, while the primary market is facing challenges in fundraising [2]

Group 1 - The company Harsanlian (SZ 002900) held its 26th meeting of the fourth board of directors on October 23, 2025, via telecommunication to discuss the appointment of the accounting firm for the year 2025 [1] - For the first half of 2025, Harsanlian's revenue composition was as follows: 86.08% from the pharmaceutical industry, 10.26% from other businesses, 2.55% from veterinary medicine, 0.94% from cosmetics, and 0.16% from functional foods [1] - As of the report date, Harsanlian's market capitalization was 4.5 billion yuan [1] Group 2 - The Chinese innovative drug sector has generated $80 billion in overseas licensing deals this year [1] - The secondary market for biopharmaceuticals is currently thriving, while the primary market is experiencing a cooling in fundraising [1]

证券代码：002900 证券简称：哈三联 公告编号：2025-066 哈尔滨三联药业股份有限公司 关于计提资产减值准备的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 | 应收账款坏账准备 | | 20,571,736.46 | 2,268,388.75 | 3,645,231.60 | 51,920.00 | | 19,142,973.61 | | --- | --- | --- | --- | --- | --- | --- | --- | | 其他应收款坏账准备 | | 4,643,743.24 | 50,938.52 | 428,506.00 | | - | 4,266,175.76 | | 存货跌 价准备 | 库存商品 | 3,434,303.26 | 30,683,760.44 | 970,616.59 | | - | 33,147,447.11 | | 原材料 | | 331,296.21 | 18,970,328.46 | 250,680.05 | | - | 19,050,944.62 | | 在产品 | | - | 5,522,599 ...

证券代码：002900 证券简称：哈三联 公告编号：2025-067 1、基本信息 | 公司名称 | 黑龙江威凯洱生物技术有限公司 | | | | | --- | --- | --- | --- | --- | | 统一社会信用代码 | 91230111560611184E | | | | | 企业性质 | 有限责任公司（自然人投资或控股） | | | | | 成立日期 | 年 日 2010 | 8 | 月 | 26 | | 法定代表人 | 姜浩 | | | | | 注册资本 | 万元 4848.5319 | | | | 哈尔滨三联药业股份有限公司 关于拟参与竞拍资产暨关联交易的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、关联交易概述 为满足战略布局及业务需要，哈尔滨三联药业股份有限公司（以下简称"公 司"）拟使用不超过 3,300 万元参与黑龙江威凯洱生物技术有限公司（以下简称 "威凯洱生物"）资产竞拍。因威凯洱生物为公司关联法人，如竞拍成功，本次 交易构成关联交易。 2025 年 10 月 23 日，公司召开第四届董事会第二十六次会议，审议通 ...